Literature DB >> 8256461

The microvascular pathophysiology of chronic venous insufficiency.

P F McDonagh1.   

Abstract

Severe chronic venous insufficiency (CVI) demonstrates as chronic, hard-to-heal wounds of the lower extremity. The wound is the result of poor skin perfusion due to a complex series of pathologic events, often initiated by a deep vein thrombosis (DVT). As years pass, the DVT causes venous valvular damage and incompetence. The calf muscle pump fails to augment venous return, and venous blood pressure is chronically elevated upon standing. Mechanisms that normally prevent the transmission of venous hypertension back upstream to the dermal microcirculation are lost. Early dermal microvascular responses include increased fluid filtration and edema. An inflammatory response induces white cell activation and adhesion. It is thought that activated white cells are trapped in dermal capillaries and increase microvascular permeability. Plasma proteins leak into the tissue space, increasing the edema. Ischemic damage to the epidermis leads to epithelial cell necrosis and ulceration. The ulcer is often slow to heal, due to inadequate perfusion and delivery of substrates required for proper wound healing. Current treatments aim to improve calf pump function, reduce edema, improve perfusion, and enhance wound healing.

Entities:  

Mesh:

Year:  1993        PMID: 8256461      PMCID: PMC2588823     

Source DB:  PubMed          Journal:  Yale J Biol Med        ISSN: 0044-0086


  21 in total

Review 1.  Lower extremity venous hemodynamics.

Authors:  G Belcaro; D Christopoulos; A N Nicolaides
Journal:  Ann Vasc Surg       Date:  1991-05       Impact factor: 1.466

Review 2.  Microvascular pattern and blood stasis in skin disease.

Authors:  T J Ryan; P W Copeman
Journal:  Br J Dermatol       Date:  1969-08       Impact factor: 9.302

3.  Hyperaemic hypoxia in venous ulceration.

Authors:  H Partsch
Journal:  Br J Dermatol       Date:  1984-02       Impact factor: 9.302

4.  Quantitative studies on the influence of leukocytes on the vascular resistance in a skeletal muscle preparation.

Authors:  M Braide; B Amundson; S Chien; U Bagge
Journal:  Microvasc Res       Date:  1984-05       Impact factor: 3.514

5.  Pericapillary fibrin in the ulcer-bearing skin of the leg: the cause of lipodermatosclerosis and venous ulceration.

Authors:  K G Burnand; I Whimster; A Naidoo; N L Browse
Journal:  Br Med J (Clin Res Ed)       Date:  1982-10-16

6.  Transcutaneous oxygen tension and capillary morphologic characteristics and density in patients with chronic venous incompetence.

Authors:  U K Franzeck; A Bollinger; R Huch; A Huch
Journal:  Circulation       Date:  1984-11       Impact factor: 29.690

Review 7.  Fluid exchange across single capillaries.

Authors:  R W Gore; P F McDonagh
Journal:  Annu Rev Physiol       Date:  1980       Impact factor: 19.318

8.  Isotope lymphography: a new method of investigating the role of the lymphatics in chronic limb oedema.

Authors:  G Stewart; J I Gaunt; D N Croft; N L Browse
Journal:  Br J Surg       Date:  1985-11       Impact factor: 6.939

9.  Positron emission tomography in venous ulceration and liposclerosis: study of regional tissue function.

Authors:  N F Hopkins; T J Spinks; C G Rhodes; A S Ranicar; C W Jamieson
Journal:  Br Med J (Clin Res Ed)       Date:  1983-01-29

10.  Transcapillary and interstitial diffusion of Na-fluorescein in chronic venous insufficiency with white atrophy.

Authors:  A Bollinger; K Jäger; A Geser; F Sgier; J Seglias
Journal:  Int J Microcirc Clin Exp       Date:  1982
View more
  2 in total

1.  Thinking Outside the Heart: Use of Engineered Cardiac Tissue for the Treatment of Chronic Deep Venous Insufficiency.

Authors:  Narine Sarvazyan
Journal:  J Cardiovasc Pharmacol Ther       Date:  2014-02-04       Impact factor: 2.457

Review 2.  Molecular Dambusters: What Is Behind Hyperpermeability in Bradykinin-Mediated Angioedema?

Authors:  Márta L Debreczeni; Zsuzsanna Németh; Erika Kajdácsi; Henriette Farkas; László Cervenak
Journal:  Clin Rev Allergy Immunol       Date:  2021-03-16       Impact factor: 8.667

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.